Literature DB >> 20803272

Smooth excimer laser coronary angioplasty (SELCA) and conventional excimer laser angioplasty: Comparison of vascular injury and smooth muscle cell proliferation.

M Oberhoff1, A Baumbach, C Herdeg, S Hassenstein, D Y Xie, E Blessing, H Hanke, K K Haase, E Betz, K R Karsch.   

Abstract

Although the excimer laser, which utilizes 'non-thermal ablation effects', has achieved encouraging results in early clinical trials, the long-term results have failed to show any advantage over conventional percutaneous transluminal coronary angioplasty (PTCA).A new system, Smooth Excimer Laser Coronary Angioplasty (SELCA), has been developed to reduce the tissue damage in the vessel wall caused by shock waves and vapour bubbles.SELCA (wavelength 308 nm, pulse duration 115 ns, repetition rate 150 Hz and energy density 50 mJ mm(-2)) lowers the amount of shock wave formation and pressure peak amplitude in the surrounding tissue by about eight times when compared to the conventional 308 nm excimer laser (ELCA). In this preclinical evaluation, this new system was compared to ELCA. Fifty New Zealand White rabbits were stimulated by repeated weak DC impulses for a period of 28 days in order to form an atherosclerotic plaque in the right carotid artery. The vessels were excised 3, 7,14 and 28 days after laser irradiation for immunohistochemical analysis.SELCA and ELCA laser treatment lead to a decrease in maximal intimal wall thickness 3 days after intervention (control: 177+/-4 microm; SELCA: 131+/-22microm; ELCA: 120 +/-33microm). In the period between 3 and 28 days, a moderate increase in intimal wall thickness was observed after SELCA treatment compared to a significant increase after ELCA (28 days after intervention: SELCA: 157+/-22microm; ELCA: 274 +/-28microm). Bromodeoxyuridine (BrdU) was applied 18 and 12 h before excision of the vessels in order to determine the percent of cells undergoing DNA synthesis. The percent of BrdU labelled SMC in the intima (control: 13 +/- 2 cells mm(-2)) increased in both groups after 3 days (SELCA: 248 +/- 107 cells mm(-2); ELCA: 162 +/- 41 cells mm(-2)) and 7 days (SELCA: 162+/- 55 cells mm(-2); ELCA: 279 +/- 119 cells mm(-2)).The present results demonstrate that vascular wall injury and increase in intimal wall thickness following SELCA are reduced in comparison to the results achieved with the conventional technique. Further trials are necessary to assess whether these improvements will lead to more favourable long-term results after excimer laser angioplasty.

Entities:  

Year:  1997        PMID: 20803272     DOI: 10.1007/BF02767155

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  27 in total

1.  Ablation of polymers and biological tissue by ultraviolet lasers.

Authors:  R Srinivasan
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

2.  Pulsed excimer laser angioplasty of human cadaveric arteries.

Authors:  E M Farrell; L A Higginson; W S Nip; V M Walley; W J Keon
Journal:  J Vasc Surg       Date:  1986-02       Impact factor: 4.268

3.  Position of the American Heart Association on research animal use.

Authors: 
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

4.  Percutaneous excimer laser coronary angioplasty.

Authors:  F Litvack; N L Eigler; J R Margolis; W S Grundfest; D Rothbaum; T Linnemeier; L B Hestrin; D Tsoi; S L Cook; D Krauthamer
Journal:  Am J Cardiol       Date:  1990-11-01       Impact factor: 2.778

5.  In vitro evaluation of ablation parameters of normal and fibrous aorta using smooth excimer laser coronary angioplasty.

Authors:  D Y Xie; S Hassenstein; M Oberhoff; H Hanke; A Baumbach; K Hohla; K K Haase; K R Karsch
Journal:  Lasers Surg Med       Date:  1993       Impact factor: 4.025

6.  Laser ablation of human atherosclerotic plaque without adjacent tissue injury.

Authors:  W S Grundfest; F Litvack; J S Forrester; T Goldenberg; H J Swan; L Morgenstern; M Fishbein; I S McDermid; D M Rider; T J Pacala
Journal:  J Am Coll Cardiol       Date:  1985-04       Impact factor: 24.094

7.  Pulsed ultraviolet lasers and the potential for safe laser angioplasty.

Authors:  W S Grundfest; I F Litvack; T Goldenberg; T Sherman; L Morgenstern; R Carroll; M Fishbein; J Forrester; J Margitan; S McDermid
Journal:  Am J Surg       Date:  1985-08       Impact factor: 2.565

8.  Percutaneous coronary excimer laser angioplasty in patients with stable and unstable angina pectoris. Acute results and incidence of restenosis during 6-month follow-up.

Authors:  K R Karsch; K K Haase; W Voelker; A Baumbach; M Mauser; L Seipel
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

9.  Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease.

Authors:  Y E Appelman; J J Piek; S Strikwerda; J G Tijssen; P J de Feyter; G K David; P W Serruys; J R Margolis; M J Koelemay; E W Montauban van Swijndregt; J J Koolen
Journal:  Lancet       Date:  1996-01-13       Impact factor: 79.321

10.  Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions.

Authors:  S Strikwerda; E Montauban van Swijndregt; D P Foley; E Boersma; V A Umans; R Melkert; P W Serruys
Journal:  J Am Coll Cardiol       Date:  1995-10       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.